# T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy

> **NCT02250209** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02250209
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250209, "T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02250209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*